Cognizant Technology Solutions Corporation
CTSH looks mispriced at 9.23x earnings for a business guiding to $5.63-$5.77 FY26 EPS, improving margins to 16.0%-16.2%, and showing demand traction with bookings up 21% and 1.4x book-to-bill.
CTSH is being priced like a no-growth, structurally impaired outsourcer even though the actual operating setup is better than that. At $42.57, the stock sits 51.1% below its 52-week high and trades at just 9.23x FY2025 EPS and 0.95x sales. That is a deep discount for a company that grew FY2025 revenue 4.3%, lifted EPS 8.0%, improved operating margin to 15.3%, and then guided FY26 adjusted EPS to $5.63-$5.77 with margins moving to 16.0%-16.2%.
The first pillar of the case is that demand is better than the stock implies. Q1 FY26 constant-currency revenue growth was 3.9%, bookings rose 21%, and book-to-bill was 1.4. More important, this was not low-quality demand. The quarter included 7 deals over $100M and 1 mega deal over $500M, with North America and large-deal ramps leading. Financial Services, a key vertical, grew over 10% CC. Management still kept full-year revenue guidance at 4.0%-6.5%, which reads cautious, but if those bookings convert on schedule the market is likely too pessimistic about second-half growth.
The second pillar is margin leverage. Project LEAP is expected to deliver $200M-$300M of 2026 savings and a full-year benefit in 2027. Even after allowing for $230M-$320M of LEAP charges in 2026, excluded from non-GAAP, the company raised adjusted operating margin guidance to 16.0%-16.2%. That matters because Q1 adjusted EPS rose 14% y/y to $1.40, well ahead of revenue growth. This is not a pure revenue story. It is an earnings-power story.
What keeps conviction at Medium instead of High is the mix of real and perceived fragility. Gross margin was down 80 bps y/y in Q1, the company explicitly warned that Q2 assumes more cautious discretionary spending, and the FY2025 cash flow line is weak at $0.2B FCF. AI is also a two-sided force. CTSH can win if it becomes a stronger AI implementation and managed services partner, helped by Atria, Google Cloud, and workforce scaling. It loses if AI simply reduces the labor content of legacy work faster than Cognizant can replace it with higher-value services. At this price, the upside from even a modest reassessment outweighs those risks.
Large-deal ramps and AI services drive growth toward the top of 4.0%-6.5%, LEAP savings stick, and investors pay a low-teens multiple on a cleaner FY27 setup.
Management delivers within the $5.63-$5.77 EPS and 16.0%-16.2% margin guide, bookings support a better 2H, and the stock rerates closer to peer multiples.
Bookings convert slowly, revenue tracks near 4.0% or below, FCF remains weak, and the market keeps CTSH near a single-digit earnings multiple.
Quant call aligns with analyst consensus (Buy: 5 buy / 6 hold / 0 sell).
The intelligent investor is a realist who sells to optimists and buys from pessimists.
Forward earnings power is better than the trailing numbers suggest: management is guiding to $5.63-$5.77 of FY26 adjusted EPS, which puts the stock at a far lower forward multiple than a business with mid-single-digit growth and rising margins usually commands. The moat today is not deep IP, it is client intimacy, delivery scale, and embedded enterprise workflows, and that moat can hold over the next 3 to 5 years if Cognizant stays relevant in AI-led modernization rather than being disintermediated by automation. AI cuts both ways here: it can compress legacy labor-based work, but CTSH is actively repositioning through Atria, Google Cloud partnerships, and scaling 5,000 Frontier Certified Engineers plus 10,000 Frontier Business Operators to capture higher-value data, cloud, and managed AI demand. Higher rates at 4.54% on the 10-year matter less to the business than to the multiple, and at 9.23x P/E much of that valuation pressure already looks priced in.
- Valuation is compressed at 9.23x P/E and 0.95x P/S versus peer averages of 17.4x and 1.6x.
- Management guides to FY26 adjusted EPS of $5.63-$5.77 and adjusted operating margin of 16.0%-16.2%, above 15.3% FY2025 operating margin.
- Demand improved in Q1 with bookings up 21% y/y, 7 deals over $100M, 1 mega deal over $500M, and book-to-bill of 1.4.
- The stock already discounts a lot of bad news, down 51.1% from the 52-week high and 35.1% below the 200-day average, while the business is still growing, with FY2025 revenue up 4.3% and FY2025 EPS up 8.0%.
- Execution has been steady: CTSH has beaten EPS estimates in 8 straight quarters, including $1.40 vs $1.34 in April 2026 and $1.39 vs $1.30 in October 2025.
- Margins are moving the right way, with FY2025 operating margin at 15.3% versus 14.7% the prior year, and management now guiding 16.0%-16.2% for FY26 on $200M-$300M of LEAP savings.
- Demand quality looks better than the market assumes, with Financial Services up over 10% CC in Q1 and management calling the recent bookings growth the strongest in the CEO's three-year tenure.
- Cash conversion is the weak spot in the current data set: FCF was only $0.2B in FY2025, versus $0.4B buybacks and $0.2B dividends, which is not a comfortable payout profile if that FCF number persists.
- Revenue guidance was not raised after a strong Q1, with FY26 still at 4.0%-6.5% CC, and Q2 guided only to 3.2%-4.7% CC because discretionary spending is still cautious.
- Gross margin already showed pressure, down 80 bps y/y in Q1 from integrated offerings, compensation costs, and bench investment, so some of the LEAP benefit may be offset operationally.
- Short interest is elevated at 12.64% of shares with 6.4 days-to-cover, signaling that a meaningful part of the market doubts the durability of the rebound.
| Metric | Value | Context |
|---|---|---|
| Current price | $42.57 | Reference price for the $67.78 target, implies 59.2% upside |
| Quant price target | $67.78 | Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $21.1B | 4.3% YoY growth |
| FY2025 EPS | $4.56 | 8.0% YoY growth |
| FY2025 operating margin | 15.3% | Up from 14.7% in the prior year |
| FY2026 adjusted EPS guide | $5.63-$5.77 | Signals stronger forward earnings power than trailing EPS |
| FY2026 adjusted operating margin guide | 16.0%-16.2% | Raised on Project LEAP savings |
| Valuation | P/E 9.23 | P/S 0.95 | Versus peer averages 17.4x P/E and 1.6x P/S |
| Balance sheet leverage | Debt/Equity 0.07 | Debt/EBITDA 0.26 | Conservative leverage profile |
| FY2025 free cash flow | $0.2B | Weak against $0.4B buybacks and $0.2B dividends |
| Q1 FY26 demand signals | Bookings +21% y/y | Book-to-bill 1.4 | Included 7 deals over $100M and 1 over $500M |
| 52-week position | $37.08-$87.03 | Current price is -51.1% from the high and -35.1% below the $65.60 200-day average |
The biggest risk is that the strong 21% bookings growth does not convert into revenue quickly enough, leaving CTSH stuck near the low end of its 4.0%-6.5% FY26 growth guide while margin gains do most of the work.
The next catalyst is Q2 earnings on July 29, 2026, especially conversion of the 1.4x book-to-bill into revenue and any update on FY26 growth versus the current cautious Q2 outlook.
Ownership is tightly institutional, with the top three holders at 90.8% and insiders at only 0.1%, which tends to make the stock more driven by fundamental revisions than founder signaling. Short interest is high at 12.64%, or 59.75M shares and 6.4 days-to-cover, which reflects real skepticism but also creates squeeze potential if July results validate the bookings story. Near-dated options positioning is mildly supportive, with a positive GEX regime and zero-gamma at $40.87, just 5.09% below spot, suggesting dealer positioning is not currently amplifying downside the way it often does in broken charts.
Q1 FY26 grew over 10% CC, the strongest vertical callout and an important proof point that discretionary spending is improving in a key client set.
Q1 FY26 growth was driven by North America and large-deal ramps, making this geography central to the second-half conversion story.
Still the weaker region in the historical read, with 2024 Q2 commentary calling Europe challenged by weak discretionary spending.
Bookings included 7 deals over $100M and 1 over $500M in Q1 FY26, supporting visibility but with lower initial margins during ramp.
CTSH held FY26 revenue guidance but raised margin guidance on Project LEAP savings.
Management has earned a decent amount of credibility. On the 2024 Q2 call, CTSH raised FY2024 adjusted EPS guidance to $4.62-$4.70 and FY2024 operating margin to 15.3%-15.5% after a revenue beat and large-deal ramps. By FY2025, the company delivered $4.56 EPS, $21.1B revenue growing 4.3%, and 15.3% operating margin, then entered FY26 guiding to $5.63-$5.77 adjusted EPS and 16.0%-16.2% adjusted operating margin. The exact 2024 adjusted EPS outcome is not provided here, so the historical comparison is incomplete, but the pattern since mid-2024 is favorable: 8 straight EPS beats, bookings improving from +5% y/y in 2024 Q2 to +21% y/y in 2026 Q1, and margin programs evolving from NextGen to LEAP with another step-up in savings. The strategy has not changed materially, it has moved from stabilization to portfolio and pyramid reshaping around AI-enabled delivery, which supports a view that management is executing rather than constantly rewriting the playbook.
For the second quarter, we expect revenue to grow 3.2% to 4.7% year-over-year in constant currency. Our second quarter guidance includes a more cautious near-term view of discretionary spending based on recent global events and trends.
The expected savings generated from the program, net of investments are enabling us to raise our 2026 adjusted operating margin guidance range to 16% to 16.2% and which represents 20 to 40 basis points of year-over-year expansion.
We delivered a solid first quarter with revenue growth in the upper half of our guidance range, expanded adjusting operating margin and strong bookings growth.
Our full year revenue guidance is unchanged at 4% to 6.5% in constant currency. The macroeconomic environment remains dynamic, and our guidance reflects a range of outcomes.
This is probably the highest bookings growth we have seen since I've been on board 3 years ago, since 3 years.
CTSH's moat is built on enterprise relationships, global delivery scale, and the operational difficulty of replacing an incumbent across complex application, infrastructure, and process environments. That moat is real but not impregnable because switching costs are highest in integrated multi-year programs, not in commoditized staff augmentation. Durability over the next 3 to 5 years depends on whether Cognizant can shift its mix toward AI-enabled transformation and managed services fast enough to defend pricing against automation.
The balance sheet is conservative, with Debt/Equity of 0.07 and Debt/EBITDA of 0.26, which gives management room to keep repurchasing stock and fund tuck-in deals. Capital deployment has been shareholder-friendly but the current FCF snapshot is the concern: $0.2B FCF versus $0.4B buybacks and $0.2B dividends is only acceptable if FY26 conversion rebounds toward the guided 90%-100% of net income. The Atria deal and prior Belcan strategy suggest management is using M&A to fill capability gaps rather than chase scale for its own sake.
CTSH rates a BUY with Medium conviction. The stock is cheap enough that it does not need heroic assumptions, only delivery against an FY26 plan that already calls for $5.63-$5.77 of adjusted EPS and better margins. The setup is attractive because demand indicators improved while the share price collapsed. The rating would weaken if July earnings show bookings are not converting, if cash flow again trails earnings badly, or if AI-related investments fail to offset pressure in legacy services. If management hits its current guide, today's 9.23x earnings multiple looks too low.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. CTSH rates a BUY at Medium conviction. The stock has been cut in half from its $87.03 52-week high and now trades at 9.23x FY2025 EPS despite management holding 4.0%-6.5% FY26 constant-currency revenue growth and raising margin guidance on Project LEAP savings. The case depends on bookings converting into second-half revenue, margin expansion holding despite near-term discretionary caution, and AI services lifting relevance rather than compressing pricing.
Investment Thesis
CTSH is being priced like a no-growth, structurally impaired outsourcer even though the actual operating setup is better than that. At $42.57, the stock sits 51.1% below its 52-week high and trades at just 9.23x FY2025 EPS and 0.95x sales. That is a deep discount for a company that grew FY2025 revenue 4.3%, lifted EPS 8.0%, improved operating margin to 15.3%, and then guided FY26 adjusted EPS to $5.63-$5.77 with margins moving to 16.0%-16.2%.
The first pillar of the case is that demand is better than the stock implies. Q1 FY26 constant-currency revenue growth was 3.9%, bookings rose 21%, and book-to-bill was 1.4. More important, this was not low-quality demand. The quarter included 7 deals over $100M and 1 mega deal over $500M, with North America and large-deal ramps leading. Financial Services, a key vertical, grew over 10% CC. Management still kept full-year revenue guidance at 4.0%-6.5%, which reads cautious, but if those bookings convert on schedule the market is likely too pessimistic about second-half growth.
The second pillar is margin leverage. Project LEAP is expected to deliver $200M-$300M of 2026 savings and a full-year benefit in 2027. Even after allowing for $230M-$320M of LEAP charges in 2026, excluded from non-GAAP, the company raised adjusted operating margin guidance to 16.0%-16.2%. That matters because Q1 adjusted EPS rose 14% y/y to $1.40, well ahead of revenue growth. This is not a pure revenue story. It is an earnings-power story.
What keeps conviction at Medium instead of High is the mix of real and perceived fragility. Gross margin was down 80 bps y/y in Q1, the company explicitly warned that Q2 assumes more cautious discretionary spending, and the FY2025 cash flow line is weak at $0.2B FCF. AI is also a two-sided force. CTSH can win if it becomes a stronger AI implementation and managed services partner, helped by Atria, Google Cloud, and workforce scaling. It loses if AI simply reduces the labor content of legacy work faster than Cognizant can replace it with higher-value services. At this price, the upside from even a modest reassessment outweighs those risks.
Key Metrics
| Metric | Value | Context | |
|---|---|---|---|
| Current price | $42.57 | Reference price for the $67.78 target, implies 59.2% upside | |
| Quant price target | $67.78 | Medium confidence, basis earnings_growth_blend | |
| FY2025 revenue | $21.1B | 4.3% YoY growth | |
| FY2025 EPS | $4.56 | 8.0% YoY growth | |
| FY2025 operating margin | 15.3% | Up from 14.7% in the prior year | |
| FY2026 adjusted EPS guide | $5.63-$5.77 | Signals stronger forward earnings power than trailing EPS | |
| FY2026 adjusted operating margin guide | 16.0%-16.2% | Raised on Project LEAP savings | |
| Valuation | P/E 9.23 | P/S 0.95 | Versus peer averages 17.4x P/E and 1.6x P/S |
| Balance sheet leverage | Debt/Equity 0.07 | Debt/EBITDA 0.26 | Conservative leverage profile |
| FY2025 free cash flow | $0.2B | Weak against $0.4B buybacks and $0.2B dividends | |
| Q1 FY26 demand signals | Bookings +21% y/y | Book-to-bill 1.4 | Included 7 deals over $100M and 1 over $500M |
| 52-week position | $37.08-$87.03 | Current price is -51.1% from the high and -35.1% below the $65.60 200-day average |
Financial Strength
The balance sheet is clearly not the issue here. Leverage is low, liquidity looks solid with a 2.23 current ratio, and debt is modest at $1.1B. Profitability is also trending in the right direction, with operating margin improving from 14.7% to 15.3% in FY2025 and guided higher again in FY26. The one item that needs monitoring is cash generation: reported FY2025 FCF of $0.2B is light for a company of this size, so the FY26 promise of 90%-100% net-income conversion needs to show up in actual cash, not just adjusted earnings.
Competitive Position
CTSH's moat is built on enterprise relationships, global delivery scale, and the operational difficulty of replacing an incumbent across complex application, infrastructure, and process environments. That moat is real but not impregnable because switching costs are highest in integrated multi-year programs, not in commoditized staff augmentation. Durability over the next 3 to 5 years depends on whether Cognizant can shift its mix toward AI-enabled transformation and managed services fast enough to defend pricing against automation.
Management & Guidance
Management's FY26 guide is balanced rather than promotional. Revenue guidance stayed at 4.0%-6.5% CC even after a strong Q1, while margin guidance was raised to 16.0%-16.2% because, as CFO Jatin Dalal said, "The expected savings generated from the program, net of investments are enabling us to raise our 2026 adjusted operating margin guidance range to 16% to 16.2% and which represents 20 to 40 basis points of year-over-year expansion." That caution matters because the same CFO also said, "For the second quarter, we expect revenue to grow 3.2% to 4.7% year-over-year in constant currency. Our second quarter guidance includes a more cautious near-term view of discretionary spending based on recent global events and trends." Credibility is helped by the 8-quarter EPS beat streak, but investors should demand revenue conversion, not just cost savings.
Segment Analysis
- Financial Services (N/A): Q1 FY26 grew over 10% CC, the strongest vertical callout and an important proof point that discretionary spending is improving in a key client set.
- North America (N/A): Q1 FY26 growth was driven by North America and large-deal ramps, making this geography central to the second-half conversion story.
- Europe (N/A): Still the weaker region in the historical read, with 2024 Q2 commentary calling Europe challenged by weak discretionary spending.
- Large deals / managed transformation programs (N/A): Bookings included 7 deals over $100M and 1 over $500M in Q1 FY26, supporting visibility but with lower initial margins during ramp.
Capital Allocation
The balance sheet is conservative, with Debt/Equity of 0.07 and Debt/EBITDA of 0.26, which gives management room to keep repurchasing stock and fund tuck-in deals. Capital deployment has been shareholder-friendly but the current FCF snapshot is the concern: $0.2B FCF versus $0.4B buybacks and $0.2B dividends is only acceptable if FY26 conversion rebounds toward the guided 90%-100% of net income. The Atria deal and prior Belcan strategy suggest management is using M&A to fill capability gaps rather than chase scale for its own sake.
Management Execution & Track Record
Management has earned a decent amount of credibility. On the 2024 Q2 call, CTSH raised FY2024 adjusted EPS guidance to $4.62-$4.70 and FY2024 operating margin to 15.3%-15.5% after a revenue beat and large-deal ramps. By FY2025, the company delivered $4.56 EPS, $21.1B revenue growing 4.3%, and 15.3% operating margin, then entered FY26 guiding to $5.63-$5.77 adjusted EPS and 16.0%-16.2% adjusted operating margin. The exact 2024 adjusted EPS outcome is not provided here, so the historical comparison is incomplete, but the pattern since mid-2024 is favorable: 8 straight EPS beats, bookings improving from +5% y/y in 2024 Q2 to +21% y/y in 2026 Q1, and margin programs evolving from NextGen to LEAP with another step-up in savings. The strategy has not changed materially, it has moved from stabilization to portfolio and pyramid reshaping around AI-enabled delivery, which supports a view that management is executing rather than constantly rewriting the playbook.
Positioning & Flows
Ownership is tightly institutional, with the top three holders at 90.8% and insiders at only 0.1%, which tends to make the stock more driven by fundamental revisions than founder signaling. Short interest is high at 12.64%, or 59.75M shares and 6.4 days-to-cover, which reflects real skepticism but also creates squeeze potential if July results validate the bookings story. Near-dated options positioning is mildly supportive, with a positive GEX regime and zero-gamma at $40.87, just 5.09% below spot, suggesting dealer positioning is not currently amplifying downside the way it often does in broken charts.
Bull Case
- The stock already discounts a lot of bad news, down 51.1% from the 52-week high and 35.1% below the 200-day average, while the business is still growing, with FY2025 revenue up 4.3% and FY2025 EPS up 8.0%.
- Execution has been steady: CTSH has beaten EPS estimates in 8 straight quarters, including $1.40 vs $1.34 in April 2026 and $1.39 vs $1.30 in October 2025.
- Margins are moving the right way, with FY2025 operating margin at 15.3% versus 14.7% the prior year, and management now guiding 16.0%-16.2% for FY26 on $200M-$300M of LEAP savings.
- Demand quality looks better than the market assumes, with Financial Services up over 10% CC in Q1 and management calling the recent bookings growth the strongest in the CEO's three-year tenure.
Bear Case
- Cash conversion is the weak spot in the current data set: FCF was only $0.2B in FY2025, versus $0.4B buybacks and $0.2B dividends, which is not a comfortable payout profile if that FCF number persists.
- Revenue guidance was not raised after a strong Q1, with FY26 still at 4.0%-6.5% CC, and Q2 guided only to 3.2%-4.7% CC because discretionary spending is still cautious.
- Gross margin already showed pressure, down 80 bps y/y in Q1 from integrated offerings, compensation costs, and bench investment, so some of the LEAP benefit may be offset operationally.
- Short interest is elevated at 12.64% of shares with 6.4 days-to-cover, signaling that a meaningful part of the market doubts the durability of the rebound.
Valuation & Price Target
Engine price target $67.78 (+59.2% vs current), Medium confidence.
- P/E Multiple: $72.19 (28% weight)
- P/S Multiple: $75.79 (20% weight)
- Quality-adjusted: $47.08 (20% weight)
- DCF: $111.93 (3% weight)
The rating stays aligned with the quant baseline BUY, but with only Medium conviction because the valuation gap is obvious while cash flow quality and peer comparability are not. The engine's $67.78 target is reasonable if CTSH delivers its $5.63-$5.77 FY26 EPS guide and the market stops valuing the company at 9.23x earnings. The caution comes from the same specifics the quant flags indirectly: wide peer P/E dispersion of 7.8x, weak reported FY2025 FCF of $0.2B, and management keeping FY26 revenue guidance unchanged despite strong Q1 bookings. Sell-side consensus is also Buy, but that is low-signal context, not the reason for the call.
Risk Assessment
Risk score 44/100 (Moderate). The biggest risk is that the strong 21% bookings growth does not convert into revenue quickly enough, leaving CTSH stuck near the low end of its 4.0%-6.5% FY26 growth guide while margin gains do most of the work.
The Bottom Line
CTSH rates a BUY with Medium conviction. The stock is cheap enough that it does not need heroic assumptions, only delivery against an FY26 plan that already calls for $5.63-$5.77 of adjusted EPS and better margins. The setup is attractive because demand indicators improved while the share price collapsed. The rating would weaken if July earnings show bookings are not converting, if cash flow again trails earnings badly, or if AI-related investments fail to offset pressure in legacy services. If management hits its current guide, today's 9.23x earnings multiple looks too low.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr